Anti-HCAR2 antibody (165-182) (STJ118060)
SPECIFICATIONS
ClonalityPolyclonal
HostRabbit
ConjugationUnconjugated
IsotypeIgG
General Information
| Short Description | Rabbit polyclonal HCAR2 (165-182) antibody for use in WB, IHC-P, IF, ICC and ELISA in human, mouse and rat samples. Datasheet included with dilution recommendations, and related reagents. |
| Applications | WB/IHC-P/IF/ICC/ELISA |
| Host | Rabbit |
| Reactivity | Human/Mouse/Rat |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Clonality | Polyclonal |
| Isotype | IgG |
| Conjugation | Unconjugated |
| Concentration | Lot specific |
| Purification | Affinity purification |
| Dilution Range | WB:1:500-1:1000IHC-P:1:50-1:200IF/ICC:1:50-1:200ELISA:Recommended starting concentration is 1 Mu g/mL. Please optimize the concentration based on your specific assay requirements. |
| Formulation | PBS with 0.09% Sodium Azide, 50% Glycerol, pH7.3. |
| Storage Instruction | Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Target Information
| Gene Symbol | HCAR2 |
| Gene ID | 338442 |
| Uniprot ID | HCAR2_HUMAN |
| Immunogen Region | 165-182 |
| Immunogen Sequence | CRLMLFMLAMNRQGSIIFLT VVAVDRYFRVVHPHHALNKI SNRTAAIISCLLWGITIGLT VHLLKKKMPIQNGGANLCSS FSICHTFQWHEAMFLLEFFL PLGIILFCSARIIWSLRQRQ MDRHAKIKRAITFIMVVAIV FVICFLPSVVVRIRIFWLLH TSGTQNCEVYRSVDLAFFIT LSFTYMNSMLDPVVYYFSSP |
| Specificity | A synthetic peptide corresponding to a sequence within amino acids 100-200 of human GPR109A/HM74A/HCAR2 (NP_808219.1). |
Additional Info
| Tissue Specificity | Expression largely restricted to adipose tissue and spleen. Expressed on mature neutrophils but not on immature neutrophils or eosinophils. |
| Function | Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide. |
| Protein Name | Hydroxycarboxylic Acid Receptor 2G-Protein Coupled Receptor 109aG-Protein Coupled Receptor Hm74aNiacin Receptor 1Nicotinic Acid Receptor |
| Database Links | Reactome: R-HSA-3296197Reactome: R-HSA-373076Reactome: R-HSA-418594 |
| Cellular Localisation | Cell MembraneMulti-Pass Membrane Protein |
| Alternative Antibody Names | Anti-Hydroxycarboxylic Acid Receptor 2 antibodyAnti-G-Protein Coupled Receptor 109a antibodyAnti-G-Protein Coupled Receptor Hm74a antibodyAnti-Niacin Receptor 1 antibodyAnti-Nicotinic Acid Receptor antibodyAnti-HCAR2 antibodyAnti-GPR109A antibodyAnti-HCA2 antibodyAnti-HM74A antibodyAnti-NIACR1 antibody |
Information sourced from Uniprot.org